12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis

USPSTF Screening Guidelines: Chlamydia & Gonorrhea

Sexually transmitted infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae are the two most common reportable bacterial infections in the United States. Untreated infections in females can ascend to the upper reproductive tract, causing Pelvic Inflammatory Disease (PID), tubal scarring, ectopic pregnancy, chronic pelvic pain, and tubal factor infertility.

The Evidence-Based Screening Mandates

• Sexually Active Females Aged <=24 Years (USPSTF Grade B): The USPSTF recommends annual screening for chlamydia and gonorrhea in all sexually active females aged 24 years and younger, regardless of reported symptoms or number of partners. High incidence rates and the predominantly asymptomatic nature of endocervical infections in young females justify universal annual screening.
• Sexually Active Females Aged >=25 Years at Increased Risk (USPSTF Grade B): The USPSTF recommends screening in females aged 25 and older who exhibit increased risk behaviors:
  • A new sexual partner or multiple sexual partners in the preceding 6 months.
  • A sexual partner diagnosed with a concurrent STI.
  • Inconsistent condom use during non-monogamous relationships.
  • Exchanging sex for money, housing, or drugs (commercial sex work).
  • A documented history of a prior bacterial STI within the past 12 months.
• Men Who Have Sex with Men (MSM): The CDC recommends at least annual screening for all sexually active MSM at all anatomical sites of exposure (pharyngeal, rectal, and urogenital). For high-risk MSM (multiple or anonymous partners, concurrent methamphetamine or substance use, or those taking HIV PrEP), screening should be performed every 3 to 6 months.
• Pregnant Persons (USPSTF Grade B): Universal screening for chlamydia and gonorrhea at the initial prenatal visit for all pregnant females aged <=24 years and older pregnant individuals at increased risk. For patients with persistent or new high-risk behaviors, repeat screening during the third trimester (ideally at 28 to 32 weeks) is mandated to prevent neonatal conjunctivitis (ophthalmia neonatorum) and chlamydial infant pneumonia.
• Asymptomatic Heterosexual Men (USPSTF Grade I): The USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of routine screening in asymptomatic heterosexual cisgender men. However, testing is clinically recommended in high-prevalence settings (adolescent clinics, correctional facilities, STI clinics) and is mandatory whenever a sexual partner is diagnosed with an STI.

---

Diagnostic Modalities: Multi-Site NAAT & Extragenital Testing

Nucleic Acid Amplification Testing (NAAT) represents the diagnostic gold standard for Chlamydia trachomatis and Neisseria gonorrhoeae due to its exceptional sensitivity (>95% to 98%) and specificity (>98% to 99%).

Preferred Specimen Types

• Cisgender Females: The single preferred specimen is a vaginal swab (either self-collected by the patient in the clinic or clinician-collected during an examination). Vaginal swabs have higher clinical sensitivity than endocervical swabs and significantly higher sensitivity than clean-catch urine. If a pelvic speculum examination is performed, an endocervical swab is an acceptable alternative.
• Cisgender Males: The preferred specimen is first-catch urine (the initial 20 to 30 mL of the voided stream). Patients must be instructed not to clean the urethral meatus prior to collection and should have abstained from urinating for at least 1 hour prior to specimen collection to ensure adequate bacterial cell concentration.

The Imperative for Multi-Site Extragenital Testing (MSM)

In individuals engaging in receptive oral or receptive anal intercourse—particularly MSM and transgender individuals—urogenital screening alone is entirely inadequate:

1. High Prevalence of Isolated Extragenital Infection: More than 70% to 85% of rectal and pharyngeal chlamydial and gonococcal infections are completely asymptomatic.
2. Diagnostic Blind Spots: Studies demonstrate that in MSM, up to 70% of gonorrhea cases and 85% of chlamydia cases are localized exclusively to the pharynx or rectum. If a primary care physician relies solely on a urine NAAT screen, the overwhelming majority of infections will be missed, allowing continued transmission and progression.
3. Pharyngeal Gonorrhea & Antimicrobial Resistance: Pharyngeal N. gonorrhoeae represents a critical biological reservoir for the development of multidrug resistance due to horizontal genetic exchange with commensal Neisseria species in the oropharynx. Furthermore, pharyngeal tissue has lower vascular perfusion; oral third-generation cephalosporins (such as cefixime) have inadequate pharyngeal penetration and high clinical failure rates. Pharyngeal gonorrhea requires high-dose intramuscular Ceftriaxone 500 mg IM single dose (1,000 mg IM if patient weight >=150 kg).

---

Syphilis Screening: USPSTF Grade A Recommendations

Syphilis, caused by the spirochete Treponema pallidum, is a multi-system, chronic vascular and mucocutaneous infection. The USPSTF issues a Grade A recommendation for syphilis screening in:

1. All asymptomatic individuals at increased risk (MSM, persons living with HIV, individuals who exchange sex for money or drugs, persons in correctional facilities, and history of prior STIs).
2. All pregnant persons during each pregnancy: Universal screening at the first prenatal visit. For individuals at high risk (unstable housing, substance use, high community prevalence, multiple partners), guidelines mandate repeat screening twice more: at 28 weeks gestation and at the time of delivery.

Clinical Staging & Manifestations

• Primary Syphilis: Characterized by the chancre—a solitary, painless, indurated, clean-based, highly infectious ulcer that appears at the site of inoculation approximately 10 to 90 days (average 21 days) post-exposure, accompanied by painless regional lymphadenopathy. Spontaneously heals within 3 to 6 weeks.
• Secondary Syphilis: Develops 2 to 8 weeks after the chancre disappears, reflecting widespread hematogenous and lymphatic spirochetemia. Cardinal features include a non-pruritic, diffuse, erythematous maculopapular or pustular rash prominently involving the palms and soles; condyloma lata (broad-based, moist, flat, highly infectious vegetative plaques in warm intertriginous and perineal folds); mucous patches (painless shallow mucosal erosions); generalized lymphadenopathy; patchy "moth-eaten" alopecia; and systemic constitutional symptoms (fever, malaise).
• Latent Syphilis: Seropositive without clinical signs or symptoms. Subdivided into:
  • Early Latent: Infection acquired within the preceding 12 months (documented seroconversion or symptom history).
  • Late Latent: Infection acquired >12 months ago or of unknown duration.
• Tertiary Syphilis: Occurs years to decades after untreated infection. Features gummatous lesions (destructive granulomatous lesions of skin and bone), cardiovascular syphilis (aortitis, aortic root dilation, aortic regurgitation, ascending aortic aneurysms), and late neurosyphilis (tabes dorsalis with sensory ataxia, Argyll Robertson pupils, general paresis). Neurosyphilis can occur at any clinical stage (e.g., syphilitic meningitis, ocular syphilis, otosyphilis).

Serologic Testing Algorithms: Traditional vs. Reverse Sequence

Because Treponema pallidum cannot be cultured on artificial media, diagnosis relies on serology. Primary care laboratories utilize two distinct diagnostic pathways:

TRADITIONAL ALGORITHM:
[Non-Treponemal Test (RPR or VDRL)]
         |
    If Reactive (Titer e.g., 1:32)
         v
[Confirmatory Treponemal Test (TP-PA or FTA-ABS)]
         |
    +----+----+
    |         |
Reactive   Non-Reactive
(Syphilis   (Biological False Positive)
Confirmed)

REVERSE SEQUENCE ALGORITHM:
[Automated Treponemal Immunoassay (EIA or CIA)]
         |
    If Reactive
         v
[Quantitative Non-Treponemal Test (RPR)]
         |
    +----+----+
    |         |
Reactive   Non-Reactive (Discordant!)
(Active     v
Syphilis)  [Second Different Treponemal Test (TP-PA)]
                |
           +----+----+
           |         |
       Reactive   Non-Reactive
       (Past Treated Syphilis  (False-Positive EIA;
       OR Untreated Late Latent  Syphilis Excluded)
       OR Early Primary)

Comparative Analysis of Non-Treponemal vs. Treponemal Tests

The Prozone Phenomenon

• Definition: The prozone phenomenon is a laboratory artifact occurring in non-treponemal testing (RPR or VDRL) where an overwhelming excess of anti-cardiolipin antibodies prevents the formation of cross-linked antigen-antibody lattices, resulting in a falsely non-reactive (negative) test result in a patient with active, florid syphilis.
• Clinical Setting: Most commonly encountered during secondary syphilis (where spirochetal burden and antibody production are extraordinarily high) and during pregnancy.
• Primary Care Management: If a patient presents with classic secondary syphilis lesions (e.g., palmoplantar rash, condyloma lata, generalized adenopathy) but their initial RPR or VDRL is reported as non-reactive, the clinician must contact the laboratory and request serum dilution (e.g., 1:16, 1:64). Diluting the serum restores the stoichiometric balance between antigen and antibody, allowing visual flocculation and yielding the true, strongly reactive high-titer result.

---

Trichomoniasis Screening & Management

Trichomonas vaginalis is a flagellated, parasitic protozoan that represents the most prevalent non-viral STI globally.

Screening Indications (CDC Guidelines)

• Women Living with HIV: Mandatory annual screening because trichomoniasis accelerates HIV genital viral shedding, increases HIV transmission to partners, and markedly elevates the risk of pelvic inflammatory disease.
• High-Prevalence Clinical Settings: Correctional facilities, high-volume STI clinics, and individuals with multiple concurrent partners.
• Symptomatic Patients: Females presenting with diffuse, malodorous, frothy, yellow-green vaginal discharge, vulvar irritation, dysuria, and dyspareunia. Physical examination reveals vaginal erythema and punctate cervical microhemorrhages ("strawberry cervix"; seen in ~2% to 5% of cases).

Diagnostic Modalities: The Inadequacy of Wet Mount Microscopy

• Saline Wet Mount Microscopy: Historically widespread; identifies motile trichomonads with jerky, spinning motility and abundant polymorphonuclear leukocytes (WBCs). However, wet mount microscopy has a dismal diagnostic sensitivity of only 50% to 60%, and trichomonad motility halts within 10 to 20 minutes of room temperature exposure, causing high false-negative rates.
• Nucleic Acid Amplification Testing (NAAT): The diagnostic gold standard for trichomoniasis. NAAT (e.g., transcription-mediated amplification on vaginal swab or urine) exhibits >95% to 100% sensitivity and specificity. The CDC strongly recommends NAAT over wet mount whenever feasible.

Evidence-Based Treatment Guidelines

• Cisgender Females: Metronidazole 500 mg orally twice daily for 7 days.
  • Critical Practice Update: A pivotal randomized controlled trial demonstrated that the historical single-dose regimen (Metronidazole 2 g PO single dose) resulted in a 19% treatment failure rate in females, whereas 7-day multi-dose therapy resulted in an 11% failure rate (a nearly 50% relative reduction in treatment failure). The single 2-g dose is no longer recommended for females.
• Cisgender Males: Metronidazole 500 mg orally twice daily for 7 days (or Metronidazole 2 g PO single dose if adherence is compromised).
• Alternative Regimen: Tinidazole 2 g orally as a single dose.
• Patient Counseling: Patients must strictly avoid alcohol consumption during metronidazole therapy and for 24 hours after completion (72 hours for tinidazole) due to the risk of severe disulfiram-like ethanol reactions (nausea, vomiting, flushing, abdominal cramps, tachycardia).
• Mandatory Re-Testing: All sexually active females treated for trichomoniasis must be re-screened with NAAT 3 months post-treatment due to high reinfection rates (~17% within 3 months).